CervoMed Inc.
CRVO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRVO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRVO
CervoMed Inc. (CRVO) is a clinical-stage biopharmaceutical company focused on developing neflamapimod for the treatment of dementia with Lewy bodies (DLB) and other neurodegenerative disorders, with a Phase 2 readout expected by year-end 2026.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$39.3M
Cash Runway
10.9 moLead Asset
neflamapimod (Phase 2)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 catalyst for CervoMed Inc..
Similar companies
CervoMed Inc. (CRVO) is a clinical-stage biopharmaceutical company focused on developing neflamapimod for the treatment of dementia with Lewy bodies (DLB) and other neurodegenerative disorders, with a Phase 2 readout expected by year-end 2026.
- Cash & equivalents of $22.5M as of 2026-06-30, with net loss of -$6.6M for the period and no revenue [sec].
- Lead candidate neflamapimod is in clinical development for DLB; a Phase 2 topline readout is expected on 2026-12-31 [catalyst].
- A private placement completed in June 2026 raised approximately $10.5M in gross proceeds, with potential for up to an additional $21.7M if warrants are fully exercised [sec · filed 2026-06-10].
- Received a U.S. patent notice of allowance in June 2026 for neflamapimod use in DLB patients without substantial AD-like tau pathology, providing IP protection into 2042 [sec · filed 2026-07-06].
- The company relies on third-party contract manufacturing organizations for drug substance and drug product supply, and has begun working with a second DP CMO to diversify sole-supplier risk [sec_mda · as of 2026-03-13].
What works
- Neflamapimod targets a specific DLB patient population (no substantial AD-like tau pathology) with a newly allowed U.S. patent extending IP protection to 2042, potentially creating a differentiated market position [sec · filed 2026-07-06].
- The company completed a private placement in June 2026 raising ~$10.5M, with additional potential proceeds of up to ~$21.7M from warrant exercises, extending its cash runway into 2027 [sec · filed 2026-06-10].
- CervoMed believes there are limited companies in later-stage development for DLB, suggesting a relatively less competitive landscape for its lead indication [sec_mda · as of 2026-03-13].
What to weigh
- The company has no approved products and no revenue, with a net loss of -$6.6M for the quarter ended 2026-06-30, and faces a going concern risk if additional financing is not secured [sec · filed 2026-07-06].
- Neflamapimod relies on single-source third-party manufacturers for drug substance and drug product, creating supply chain vulnerability despite efforts to diversify [sec_mda · as of 2026-03-13].
- The company faces significant competition from larger pharmaceutical and biotech firms pursuing treatments for DLB and other neurodegenerative diseases [sec_mda · as of 2026-03-13].
- CervoMed's ability to advance neflamapimod into Phase 3 depends on successfully entering a partnership, which may not occur on acceptable terms or at all [sec · filed 2026-07-06].
From the filings
Quoted directly from source documents.
Private placement gross proceeds of ~$10.5M
“The gross proceeds for the Private Placement are expected to be approximately $10.5 million”
SEC filings · June 10, 2026
Patent notice of allowance for neflamapimod in DLB with no substantial AD-like tau pathology
“received a notice of allowance from the United States Patent and Trademark Office related to a new patent protecting the Company's use of neflamapimod for the treatment of DLB in patients with no substantial AD-like tau pathology”
SEC filings · July 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · neflamapimod — Phase 2 Readout: neflamapimod — Topline results from the Phase 2 trial of neflamapimod in DLB are expected, which will be a key value inflection point for the program.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — CervoMed has no commercial products and no revenue; net loss of -$6.6M in Q2 2026 [sec].
- Dependence on single-source manufacturers — Relies on third-party CMOs for drug substance and drug product; supply could be interrupted [sec_mda · as of 2026-03-13].
- Need for partnership to advance Phase 3 — Company may not secure a partner for Phase 3 DLB trial on acceptable terms or at all [sec · filed 2026-07-06].
- Intense competition in neurodegenerative space — Many established firms are pursuing DLB and AD therapies, though CervoMed sees limited late-stage DLB competitors [sec_mda · as of 2026-03-13].
What to watch
- Phase 2 topline data for neflamapimod in DLB expected on 2026-12-31 [catalyst].
- Exercise of warrants from the June 2026 private placement, which could provide up to $21.7M in additional capital [sec · filed 2026-06-10].
- Progress in securing a partnership to advance neflamapimod into Phase 3 for DLB [sec · filed 2026-07-06].
- Manufacturing diversification efforts with a second drug product CMO [sec_mda · as of 2026-03-13].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated August 19, 2026 · How we verify sources →
Run CervoMed Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CervoMed Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.9 months
D/E 0.13
Lead: Phase 2
1 candidate
1 upcoming, next in ~123d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$8.2M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 739,892 | $2.9M |
| vanguard capital management llc | 632,404 | $2.5M |
| millennium management llc | 208,908 | $823K |
| geode capital management, llc | 74,371 | $293K |
| renaissance technologies llc | 63,904 | $252K |
| blackrock, inc. | 51,660 | $204K |
| xtx topco ltd | 38,487 | $152K |
| citizens financial group inc/ri | 37,477 | $148K |
| vanguard fiduciary trust co | 36,151 | $142K |
| northern trust corp | 30,044 | $118K |
Showing top 10 of 36 institutional holders of CervoMed Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.4%
- Days to cover
- 7.5
- Shares short
- 281,907
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRVO short interestGovernance
Frequently asked questions
What is the AI investment thesis for CervoMed Inc.?
CervoMed Inc. (CRVO) is a clinical-stage biopharmaceutical company focused on developing neflamapimod for the treatment of dementia with Lewy bodies (DLB) and other neurodegenerative disorders, with a Phase 2 readout expected by year-end 2026.
What is CervoMed Inc.'s lead drug candidate?
CervoMed Inc.'s most advanced tracked candidate is neflamapimod (Phase 2) for dementia with Lewy bodies (DLB).
What is CervoMed Inc.'s next catalyst?
CervoMed Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: neflamapimod" — expected December 31, 2026.
Who is the CEO of CervoMed Inc.?
Dr. John J. Alam M.D. is the chief executive officer of CervoMed Inc. (CRVO).
Where is CervoMed Inc. headquartered?
CervoMed Inc. (CRVO) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.